Cel Stroke disables millions worldwide and costs the EU €38 billion each year. Excitingly, my team has identified a clinically-feasible therapy for stroke which reverses disability in rats when given in a clinically-relevant time frame. Specifically, we have shown that the human growth factor neurotrophin 3 (NT3) promotes locomotor recovery and reverses sensory neglect in adult rats when infused into disabled arm muscles, starting 24 hours after stroke. Importantly, Phase II clinical trials have shown that systemic, repeated high doses of neurotrophin-3 are safe and well-tolerated in humans with other conditions. This paves the way for a Phase II trial in humans after stroke.We now wish to maximise arm and hand (paw) recovery in elderly rats with larger strokes by optimising dose, timing and route. We will then submit for approval a Clinical Trial Application for a randomised, double-blinded, placebo-controlled Phase II human clinical trial to treat stroke using NT3.We also propose multidisciplinary, cutting-edge studies to understand how NT3 promotes plasticity in the brain and spinal cord. 1) We will use wireless neural recording in awake rats and functional brain imaging to study plasticity after stroke and NT3 treatment. 2) Our innovative “RatBot” will automatically train, rehabilitate and assess grasping of pellet food. 3) To reveal where NT3 is transported we will track a novel tagged version of NT3 in vivo. 4) In an ambitious final study we will maximise recovery of arm and hand function in elderly rats when treatments are delayed by 1 month after larger strokes.In summary, we propose a high-risk, high-yield, transdisciplinary, innovative programme of work to maximise sensory and motor recovery after stroke in elderly rats. Treatment will be initiated in a clinically-relevant time frame (after 24 hours or 1 month) using a clinically-relevant dose and duration of treatment via a clinically-straightforward route, ready for a Phase II clinical trial. Dziedzina nauki medical and health sciencesbasic medicineneurologystroke Program(-y) FP7-IDEAS-ERC - Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) Temat(-y) ERC-SG-LS5 - ERC Starting Grant - Neurosciences and neural disorders Zaproszenie do składania wniosków ERC-2012-StG_20111109 Zobacz inne projekty w ramach tego zaproszenia System finansowania ERC-SG - ERC Starting Grant Instytucja przyjmująca KING'S COLLEGE LONDON Wkład UE € 1 499 909,00 Adres STRAND WC2R 2LS London Zjednoczone Królestwo Zobacz na mapie Region London Inner London — West Westminster Rodzaj działalności Higher or Secondary Education Establishments Kierownik naukowy Lawrence David Falcon Moon (Dr.) Kontakt administracyjny Paul Labbett (Mr.) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych Beneficjenci (1) Sortuj alfabetycznie Sortuj według wkładu UE Rozwiń wszystko Zwiń wszystko KING'S COLLEGE LONDON Zjednoczone Królestwo Wkład UE € 1 499 909,00 Adres STRAND WC2R 2LS London Zobacz na mapie Region London Inner London — West Westminster Rodzaj działalności Higher or Secondary Education Establishments Kierownik naukowy Lawrence David Falcon Moon (Dr.) Kontakt administracyjny Paul Labbett (Mr.) Linki Kontakt z organizacją Opens in new window Strona internetowa Opens in new window Koszt całkowity Brak danych